 The purpose of this study is to evaluate the safety and efficacy of siltuximab in participants with relapsed the return of a disease or the signs and symptoms of a disease after a period of improvement. or refractory cancer that does not respond to treatment multiple myeloma a type of cancer that begins in plasma cells white blood cells that produce antibodies. 